| Unique ID issued by UMIN | UMIN000059628 |
|---|---|
| Receipt number | R000068199 |
| Scientific Title | Immunological Mechanisms of Chronic Nasopharyngitis and Therapeutic Effects of Epipharyngeal Abrasive Therapy (EAT) |
| Date of disclosure of the study information | 2025/11/04 |
| Last modified on | 2025/11/03 21:58:11 |
Study on the Therapeutic Effects of Epipharyngeal Abrasive Therapy (EAT) and Immune Profile Changes in Chronic Nasopharyngitis
Chronic Nasopharyngitis and EAT Effects
Immunological Mechanisms of Chronic Nasopharyngitis and Therapeutic Effects of Epipharyngeal Abrasive Therapy (EAT)
Immune Profiling and EAT Effects in Chronic Nasopharyngitis
| Japan |
Chronic Nasopharyngitis
| Oto-rhino-laryngology |
Others
NO
To quantitatively evaluate immune profile changes before and after Epipharyngeal Abrasive Therapy (EAT) in patients with chronic nasopharyngitis using flow cytometry of scraped epithelial cells and peripheral blood. The study also aims to identify disease-specific immune characteristics by comparing with healthy controls.
Others
This study aims to quantitatively assess immune profile changes in chronic nasopharyngitis and clarify the immunomodulatory effects of Epipharyngeal Abrasive Therapy (EAT).
Exploratory
Explanatory
Not applicable
Change in CD4/CD8 ratio in scraped epithelial cells and peripheral blood before and after EAT (evaluated at baseline and 3 months after treatment)
Change in Th17/Treg ratio (baseline and 3 months)
Transition of subjective symptom scores (VAS) at baseline, 1 month, and 3 months
Change in endoscopic inflammatory findings (baseline and 3 months)
Comparison of immune profiles with healthy controls
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Treatment
| Maneuver |
Patients with chronic nasopharyngitis will receive Epipharyngeal Abrasive Therapy (EAT) once a week for 4 weeks. Peripheral blood and epipharyngeal swab samples will be collected before and after the intervention to evaluate changes in immune cell composition.
| 15 | years-old | <= |
| 70 | years-old | >= |
Male and Female
Participants diagnosed with chronic nasopharyngitis, aged 15 years or older, who consent to EAT and understand the study purpose and provide written informed consent.
Individuals with severe systemic diseases, those using immunosuppressive agents, pregnant or breastfeeding women, or those deemed inappropriate by the principal investigator.
40
| 1st name | Manabu |
| Middle name | |
| Last name | Mogitate |
Mogitate Medical Corporation
Mogitate ENT Clinic
2130011
4F-401, Sekiguchi Daiichi Building, 1-2-5 Hisamoto, Takatsu-ku, Kawasaki-shi, Kanagawa, Japan
0448654187
mogitateentjp@m08.itscom.net
| 1st name | Manabu |
| Middle name | |
| Last name | Mogitate |
Mogitate Medical Corporation
Mogitate ENT Clinic
2130011
4F-401, Sekiguchi Daiichi Building, 1-2-5 Hisamoto, Takatsu-ku, Kawasaki-shi, Kanagawa, Japan
0448654187
mogitateentjp@m08.itscom.net
Mogitate Medical Corporation
Manabu Mogitate
Mogitate Medical Corporation
Other
Manabu Mogitate
Institutional Review Board: Ota General Hospital Ethics Committee
1-50 Nisshin-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan
0442440131
info@ota-g-hospital.com
NO
| 2025 | Year | 11 | Month | 04 | Day |
Unpublished
Preinitiation
| 2025 | Year | 11 | Month | 03 | Day |
| 2025 | Year | 11 | Month | 04 | Day |
| 2026 | Year | 11 | Month | 03 | Day |
| 2025 | Year | 11 | Month | 03 | Day |
| 2025 | Year | 11 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068199